MODERN TREATMENT PRINCIPLES OF ANEMIA IN CHRONIC HEART FAILURE
Keywords:
chronic heart failure, dapagliflozin, anemia, ferritinAbstract
The study comparatively examined the impact of standard therapy, including dapagliflozin, a type 2 sodium glucose cotransporter inhibitor, on hematological changes and intracardiac hemodynamics in patients with anemia and chronic heart failure. The increase in erythropoietin levels in the group of patients receiving dapagliflozin after treatment is associated with the drug's stimulating effect on erythropoietin production in the kidneys.
References
Ansary TM, Nakano D, Nishiyama A. Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System. Int J Mol Sci.2019;20(3):629. doi:10.3390/ijms20030629.
Aбдуллaeв Т.A., Цoй И.A. Прoблeмa aнeмичeскoгo синдрoмa при ХСН: критичeский oбзoр рeзультaтoв исслeдoвaния RED-HF и сoбствeнныe дaнныe/ Журнaл сeрдeчнaя нeдoстaтoчнoсть. Мoсквa 2016, №3 С.44-65.
Caughey M.C., Avery C.L., Ni H., Solomon S.D., Matsushita K., Wruck L.M. et al. Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance). Am. J. Cardiol. 2014; 114(12): 1850–4. DOI: 10.1016/j. amjcard.2014.09.024.
Costa E., Lima M., Alves J.M., Rocha S., Rocha-Pereira P., Castro E. et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J. Clin. Immunol. 2008; 28(3): 268–75. DOI: 10.1007/s10875-007-9168-x.
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761-72. doi:10.1038/s41569-020-0406-8.
De Fronzo, R.A.; Norton, L.; Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev.Nephrol. 2017, 13, 11–26.
Docherty KF, Curtain JP, Anand IS, Bengtsson O, Inzucchi SE, Køber L, et al. Effect of dapagliflozin on anaemia in DAPA-HF. Eur J Heart Fail. 2021;23(4):617-628. doi: 10.1002/ejhf.2132.
Docherty KF, Petrie MC. Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart. 2022;108(4):312-320. doi: 10.1136/heartjnl-2020-318658.
Ferreira JP, Anker SD, Butler J, Filippatos G, Iwata T, Salsali A, et al. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. Eur J Heart Fail. 2022;24(4):708-715. doi: 10.1002/ejhf.2409.
Gadayev A.G., Turaqulov R.I., Kurbanov A.K., Rahimova M.E. Role of Hepcidin and Pro-Inflammatory Cytocines in Chonic Heart Failure in Combination with Anemia // Central Asian Journal of medicine.-2019., Vol.2019: Iss 3, Article 11., P. 81-92.
Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, et al. Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. J Clin Endocrinol Metab. 2020;105(4):dgaa057. doi: 10.1210/clinem/dgaa057.
Inzucchi, S.E.; Zinman, B.; Fitchett, D.; Wanner, C.; Ferrannini, E.; Schumacher, M.; Schmoor, C.; Ohneberg, K.; Johansen, O.E.; George, J.T.; et al. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights from a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2018, 41, 356–363.
Ishani A., Weinhandl E., Zhao Z., Gilbertson D.T., Collins A.J., Yusuf S. et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 2005; 45(3): 391–9. DOI: 10.1016/j.jacc.2004.10.038.
Jackson, A.; Dewan, P.; Anand, I.; Belohlavek, J.; Bengtsson, O.; de Boer, R.; Böhm, M.; Boulton, D.; Chopra, V.; Demets, D.; et al. Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation 2020, 142, 1040–1054.
Jongs, N.; Chertow, G.M.; Greene, T.; McMurray, J.J.V.; Langkilde, A.M.; Correa-Rotter, R.; Kashihara, N.; Rossing, P.; Sjostrom, C.D.; Stefansson, B.V.; et al. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD. J. Am. Soc. Nephrol. 2022, 33, 2094–2107.
Karg, M.V.; Bosch, A.; Kannenkeril, D.; Striepe, K.; Ott, C.; Schneider, M.P.; Boemke-Zelch, F.; Linz, P.; Nagel, A.M.; Titze, J.; et al. SGLT-2-Inhibition with Dapagliflozin Reduces Tissue Sodium Content: A Randomised Controlled Trial. Cardiovasc. Diabetol. 2018, 17, 5.
Kolkailah, A.A.; Wiviott, S.D.; Raz, I.; Murphy, S.A.; Mosenzon, O.; Bhatt, D.L.; Leiter, L.A.; Wilding, J.P.H.; Gause-Nilsson, I.; Sabatine, M.S.; et al. Effect of Dapagliflozin on Hematocrit in Patients with Type 2 Diabetes at High Cardiovascular Risk: Observations from DECLARE-TIMI 58. Diabetes Care 2022, 45, e27–e29.
Lambers Heerspink, H.J.; de Zeeuw, D.; Wie, L.; Leslie, B.; List, J. Dapagliflozin a Glucose-Regulating Drug with Diuretic Properties in Subjects with Type 2 Diabetes. Diabetes Obes. Metab. 2013, 15, 853–862.
Li, J.; Woodward, M.; Perkovic, V.; Figtree, G.A.; Heerspink, H.J.L.; Mahaffey, K.W.; de Zeeuw, D.; Vercruysse, F.; Shaw, W.;Matthews, D.R.; et al. Mediators of the Effects of Canagliflozin on Heart Failure in Patients with Type 2 Diabetes. JACC Heart Fail.2020, 8, 57–66.
Marazia S., Loderini S., Magliari F., Sarullo F.M., Di Mauro M. Sucrosomial iron supplementation can be a useful support treatment in patients with heart failure and anemia. In: Materials of 5th International Multidisciplinary Course on Iron Anemia. Florence, Italy. March 31 — April 1, 2017.
Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, et al. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation. 2020;141(8):704-707. doi: 10.1161/CIRCULATIONAHA.119.044235.
Mc Causland, F.R.; Claggett, B.L.; Vaduganathan, M.; Desai, A.S.; Jhund, P.; de Boer, R.A.; Docherty, K.; Fang, J.; Hernandez, A.F.; Inzucchi, S.E.; et al. Dapagliflozin and Kidney Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2023, 8, 56–65.
Petrie MC, Verma S, Docherty KF, et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020 Mar 27. doi:10.1001/jama.2020.1906.
Rizzo C, Carbonara R, Ruggieri R, et al. Iron deficiency: a new target for patients with heart failure. Front Cardiovasc Med. 2021;908. doi:10.3389/fcvm.2021.709872.
Sano, M.; Goto, S. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation 2019, 139, 1985–1987.
Sano, M.; Takei, M.; Shiraishi, Y.; Suzuki, Y. Increased Hematocrit during Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys. J. Clin. Med. Res. 2016, 8, 844–847.
Sen, T.; Heerspink, H.J.L. A Kidney Perspective on the Mechanism of Action of Sodium Glucose Co-Transporter 2 Inhibitors. Cell Metab. 2021, 33, 732–739.
Sha, S.; Polidori, D.; Heise, T.; Natarajan, J.; Farrell, K.; Wang, S.-S.; Sica, D.; Rothenberg, P.; Plum-Mörschel, L. Effect of the Sodium Glucose Co-Transporter 2 Inhibitor Canagliflozin on Plasma Volume in Patients with Type 2 Diabetes Mellitus. Diabetes Obes. Metab. 2014, 16, 1087–1095.
Гaдaeв A.Г., Турaкулoв Р.И., Қурбoнoв A.К., Тoшeвa Х.Б., Эркинoвa Н.A. Сурункaли юрaк eтишмoвчилиги кaмқoнлик билaн кeчгaндa дaвoлaш тaмoйиллaри // Тoшкeнт тиббиёт aкaдeмияси aхбoрoтнoмaси. – 2014. - №4. - С.71 -73. (14.00.00; №13).
Гaдaeв A.Г., Турaкулoв Р.И., Рaхимoвa М.Э. Cурункaли юрaк eтишмoвчилиги кaмқoнлик билaн кeчгaндa бeмoрлaрнинг ҳaёт сифaти вa жисмoний юклaмaгa чидaмлилик кўрсaткичлaри // Тoшкeнт тиббиёт aкaдeмияси aхбoрoтнoмaси. – 2014. - №4. – С.71 – 73. 38
